Suppr超能文献

含或不含N端甲硫氨酸的重组人生长激素的等效效价和药代动力学

Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine.

作者信息

Moore J A, Rudman C G, MacLachlan N J, Fuller G B, Burnett B, Frane J W

机构信息

Department of Pharmacological Sciences, Genentech, Inc. South San Francisco, California 94080.

出版信息

Endocrinology. 1988 Jun;122(6):2920-6. doi: 10.1210/endo-122-6-2920.

Abstract

Two forms of human GH (hGH) have been produced by recombinant DNA technology. One form has an amino acid sequence identical to that of the natural pituitary hormone (rhGH) and the other form has an additional N-terminal methionine (Met-hGH). The biological potencies of these 2 polypeptides have been compared in hypophysectomized rats in a multidose study measuring body weights and several long bone growth parameters. The pharmacokinetic profiles after iv and sc injection were determined in cynomolgus monkeys in a 4-period cross-over study. All of the measured parameters in all the studies indicated that there was no difference in the two forms of hGH. Measurements taken after 27 daily injections of rhGH or Met-hGH (30-500 micrograms/kg.day) indicated that femur length and width of the proliferative zone in the tibial epiphysis showed dose-related effects for both forms of hGH but no difference between them. The relative potency, based on body weight gain, was calculated using a parallel line bioassay. Weight gain after 8 daily injections in the 5-dose long bone growth study indicated a rhGH potency of 0.80 (95% confidence interval, 0.5-1.23) relative to Met-hGH. It was concluded that the presence of an N-terminal methionine on hGH has no effect on potency in this model. The pharmacokinetic parameters after iv administration were estimated by fitting serum concentration-time data to a 2-compartment model. Parameters after sc injection were computed by compartment-independent methods. Met-hGH and rhGH had very similar pharmacokinetic profiles after both routes of administration. Comparison of the pharmacokinetic parameters indicated that the clearance after iv administration (rhGH, 15 ml/min; Met-hGH, 13 ml/min) and the sc bioavailability (rhGH, 0.72 +/- 0.21; Met-hGH, 0.59 +/- 0.21) were not significantly different for the 2 forms of hGH. It was concluded that rhGH and Met-hGH have equivalent bioavailability and pharmacokinetics in cynomolgus monkeys.

摘要

通过重组DNA技术已产生了两种形式的人生长激素(hGH)。一种形式的氨基酸序列与天然垂体激素(rhGH)相同,另一种形式在N端有一个额外的甲硫氨酸(Met-hGH)。在一项多剂量研究中,对垂体切除的大鼠比较了这两种多肽的生物学效价,该研究测量了体重和几个长骨生长参数。在一项为期4个周期的交叉研究中,测定了食蟹猴静脉注射和皮下注射后的药代动力学特征。所有研究中测量的所有参数表明,两种形式的hGH没有差异。在每日注射rhGH或Met-hGH(30 - 500微克/千克·天)27天后进行的测量表明,两种形式的hGH对股骨长度和胫骨骨骺增殖区宽度均显示出剂量相关效应,但两者之间无差异。基于体重增加,使用平行线生物测定法计算相对效价。在5剂量长骨生长研究中,每日注射8次后的体重增加表明,相对于Met-hGH,rhGH的效价为0.80(95%置信区间,0.5 - 1.23)。得出的结论是,hGH上N端甲硫氨酸的存在对该模型中的效价没有影响。静脉给药后的药代动力学参数通过将血清浓度-时间数据拟合到二室模型进行估算。皮下注射后的参数通过非房室方法计算。两种给药途径后,Met-hGH和rhGH的药代动力学特征非常相似。药代动力学参数的比较表明,两种形式的hGH静脉给药后的清除率(rhGH,15毫升/分钟;Met-hGH,13毫升/分钟)和皮下生物利用度(rhGH,0.72±0.21;Met-hGH,0.59±0.21)没有显著差异。得出的结论是,rhGH和Met-hGH在食蟹猴中具有等效的生物利用度和药代动力学。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验